Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients.

International journal of clinical pharmacy - 1 Aug 2020

Ebid Abdel-Hameed Ibrahim Mohamed, Ahmed Ossama Ashraf, Agwa Sara Hassan, Abdel-Motaleb Sara Mohamed, Hagag Radwa Samir

Abstract excerpt

Background Hepatitis C virus infection is one of the major causes of liver cirrhosis and hepatocellular carcinoma worldwide. IL28B gene polymorphism has a direct relation to the response of interferon-based regimens. However, the effect of IL28B gene polymorphism on efficacy of the new direct acting antivirals used in treatment of chronic hepatitis C Egyptian patients hasn't been studied yet. Objective This study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Interferons

Share to Liver Cirrhosis

Share to Treatment Outcome

Source

Identifiers

PMID: 32712884
DOI: 10.1007/s11096-020-01085-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients.PMID 32712884Read ↗

Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients.Semantic proximity Read ↗

Impact of Interleukin 28B and ICAM-1 Genetic Polymorphisms on Response to Direct Antiviral Treatment Among HCV Infected Patients.Semantic proximity Read ↗

Interleukin 28B polymorphisms and therapy response in Egyptian hepatitis C genotype-4 patients.Semantic proximity Read ↗

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsSemantic proximity Read ↗

Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms?Semantic proximity Read ↗

IL28B rs12979860 gene polymorphism in Egyptian patients with chronic liver disease infected with HCV.Semantic proximity Read ↗

Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?Semantic proximity Read ↗

Association of IL28 B and IL10 Polymorphism with HCV Infection and Direct Antiviral Treatment.Semantic proximity Read ↗

Role of Interleukin 28B Polymorphisms in Response to Interferon Based Therapy for Hepatitis C Virus Clearance.Semantic proximity Read ↗

Role of viral and host factors in interferon based therapy of hepatitis C virus infection.Semantic proximity Read ↗

Interleukin 28B.rs12979860 genotype does not affect hepatitis C viral load in Egyptians with genotype 4 chronic infection.Semantic proximity Read ↗

Predictive power of Interleukin-28B gene variants for outcome of Hepatitis C Virus genotype 4 in Egyptians: A systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.